209 related articles for article (PubMed ID: 35582542)
1. Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance.
Khalil MI; De Benedetti A
Cancer Drug Resist; 2022; 5(1):93-101. PubMed ID: 35582542
[TBL] [Abstract][Full Text] [Related]
2. Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.
Singh V; Jaiswal PK; Ghosh I; Koul HK; Yu X; De Benedetti A
Int J Cancer; 2019 Aug; 145(4):1055-1067. PubMed ID: 30737777
[TBL] [Abstract][Full Text] [Related]
3. NEK1 Phosphorylation of YAP Promotes Its Stabilization and Transcriptional Output.
Khalil MI; Ghosh I; Singh V; Chen J; Zhu H; De Benedetti A
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33297404
[TBL] [Abstract][Full Text] [Related]
4. Targeting Prostate Cancer, the 'Tousled Way'.
Bhoir S; De Benedetti A
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446279
[TBL] [Abstract][Full Text] [Related]
5. TLK1-mediated MK5-S354 phosphorylation drives prostate cancer cell motility and may signify distinct pathologies.
Khalil MI; Singh V; King J; De Benedetti A
Mol Oncol; 2022 Jul; 16(13):2537-2557. PubMed ID: 35064619
[TBL] [Abstract][Full Text] [Related]
6. The TLK1-Nek1 axis promotes prostate cancer progression.
Singh V; Jaiswal PK; Ghosh I; Koul HK; Yu X; De Benedetti A
Cancer Lett; 2019 Jul; 453():131-141. PubMed ID: 30928383
[TBL] [Abstract][Full Text] [Related]
7. The TLK1/Nek1 axis contributes to mitochondrial integrity and apoptosis prevention via phosphorylation of VDAC1.
Singh V; Khalil MI; De Benedetti A
Cell Cycle; 2020 Feb; 19(3):363-375. PubMed ID: 31914854
[TBL] [Abstract][Full Text] [Related]
8. Interaction of TLK1 and AKTIP as a Potential Regulator of AKT Activation in Castration-Resistant Prostate Cancer Progression.
Khalil MI; Madere C; Ghosh I; Adam RM; De Benedetti A
Pathophysiology; 2021 Jul; 28(3):339-354. PubMed ID: 35366279
[TBL] [Abstract][Full Text] [Related]
9. NEK1-Mediated Phosphorylation of YAP1 Is Key to Prostate Cancer Progression.
Ghosh I; Khalil MI; Mirza R; King J; Olatunde D; De Benedetti A
Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979713
[TBL] [Abstract][Full Text] [Related]
10. The TLK1-MK5 Axis Regulates Motility, Invasion, and Metastasis of Prostate Cancer Cells.
Khalil MI; De Benedetti A
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497211
[TBL] [Abstract][Full Text] [Related]
11. Generation of Phenothiazine with Potent Anti-TLK1 Activity for Prostate Cancer Therapy.
Singh V; Bhoir S; Chikhale RV; Hussain J; Dwyer D; Bryce RA; Kirubakaran S; De Benedetti A
iScience; 2020 Sep; 23(9):101474. PubMed ID: 32905878
[TBL] [Abstract][Full Text] [Related]
12. Identification of the proteome complement of humanTLK1 reveals it binds and phosphorylates NEK1 regulating its activity.
Singh V; Connelly ZM; Shen X; De Benedetti A
Cell Cycle; 2017 May; 16(10):915-926. PubMed ID: 28426283
[TBL] [Abstract][Full Text] [Related]
13. New insights for drug resistance in metastatic castration-resistant prostate cancer.
Kushwaha PP; Gupta S
Cancer Drug Resist; 2022; 5(3):846-849. PubMed ID: 36176749
[TBL] [Abstract][Full Text] [Related]
14. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
15. Role of androgen receptor splice variants in prostate cancer metastasis.
Xu J; Qiu Y
Asian J Urol; 2016 Oct; 3(4):177-184. PubMed ID: 28239558
[TBL] [Abstract][Full Text] [Related]
16. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
Tilki D; Schaeffer EM; Evans CP
Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
18. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
19. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC
Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
